Bortezomib (Velcade)
Also known as PS-341.
General information
Class/mechanism: Reversible inhibitor of the 26S proteasome, interfering with degradation of ubiquitinated proteins. This disrupts normal homeostatic mechansims, leading to cell death.[1][2][3]
Route: IV, SC
Extravasation: irritant
- Use antiviral prophylaxis (such as with acyclovir (Zovirax) 400 mg PO daily or valacyclovir (Valtrex) 250-500 mg PO daily) to decrease risk of reactivating herpes zoster in patients treated with Bortezomib (Velcade)[4]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bortezomib (Velcade) patient drug information (Chemocare)[5]
- Patient counseling information can be found on page 35 of the package insert[1]
- Bortezomib (Velcade) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 Bortezomib (Velcade) package insert
- ↑ Bortezomib (Velcade) package insert (locally hosted backup)
- ↑ Velcade manufacturer's website
- ↑ Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009 Jan 1;115(1):229-32. link to original article PubMed
- ↑ Bortezomib (Velcade) patient drug information (Chemocare)
- ↑ Bortezomib (Velcade) patient drug information (UpToDate)